This site is intended for health professionals only!

Published on 3 July 2007

Share this story:

Enoxaparin trumps UFH across board


A meta-analysis comparing enoxaparin with unfractionated heparin (UFH) in all acute coronary syndromes (ACS) concludes that overall, enoxaparin gives better outcomes: a higher incidence of major bleeding is outweighed by fewer serious cardiovascular events.

The authors note that while anti-thrombin therapy is an established central treatment in ACS, it is still unclear which drug gives best results overall. There is considerable trial data available for the low-molecular-weight heparin enoxaparin, and the aim of this analysis was to determine whether this is associated with a better balance of risk and safety than UFH.

The authors carried out a literature search for controlled trials comparing enoxaparin with UFH in patients with ACS

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: